Seeking better outcomes for patients

CytRx Corporation is a biopharmaceutical company focused on the discovery and development of new therapeutics to treat patients with high unmet medical needs

Learn More

CytRx has both near-term potential milestone/royalty payments and a pipeline of additional next-gen candidates

Aldoxorubicin: 1st Gen LADR Partnered with ImmunityBio ​Trials have proven safety of higher dosing and efficacy​

CytRx milestones and royalties from KemPharm for Arimoclomol​